Cargando…

Targeted Endoradiotherapy with Lu(2)O(3)-iPSMA/-iFAP Nanoparticles Activated by Neutron Irradiation: Preclinical Evaluation and First Patient Image

Prostate-specific membrane antigen (PSMA) is expressed in a variety of cancer cells, while the fibroblast activation protein (FAP) is expressed in the microenvironment of tumors. Previously, we reported the ability of iPSMA and iFAP ligands to specifically target PSMA and FAP proteins, as well as th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luna-Gutiérrez, Myrna, Ocampo-García, Blanca, Jiménez-Mancilla, Nallely, Ancira-Cortez, Alejandra, Trujillo-Benítez, Diana, Hernández-Jiménez, Tania, Ramírez-Nava, Gerardo, Hernández-Ramírez, Rodrigo, Santos-Cuevas, Clara, Ferro-Flores, Guillermina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026501/ https://www.ncbi.nlm.nih.gov/pubmed/35456554 http://dx.doi.org/10.3390/pharmaceutics14040720

Ejemplares similares

Toxicity Assessment of [(177)Lu]Lu−iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes
por: Hernández-Jiménez, Tania, et al.
Publicado: (2022)

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using (177)Lu-iPSMA and (177)Lu-DOTATOC: Experience after 905 Treatment Doses
por: Luna-Gutiérrez, Myrna, et al.
Publicado: (2023)

[(99m)Tc]Tc-iFAP Radioligand for SPECT/CT Imaging of the Tumor Microenvironment: Kinetics, Radiation Dosimetry, and Imaging in Patients
por: Coria-Domínguez, Luis, et al.
Publicado: (2022)

Design, Synthesis and Preclinical Assessment of (99m)Tc-iFAP for In Vivo Fibroblast Activation Protein (FAP) Imaging
por: Trujillo-Benítez, Diana, et al.
Publicado: (2022)

[(99m)Tc]Tc-iFAP/SPECT Tumor Stroma Imaging: Acquisition and Analysis of Clinical Images in Six Different Cancer Entities
por: Vallejo-Armenta, Paola, et al.
Publicado: (2022)

Synthesis and Preclinical Evaluation of (177)Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer
por: Wurzer, Alexander, et al.
Publicado: (2022)

Synthesis and Evaluation of (177)Lu-DOTA-PD-L1-i and (225)Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy
por: Luna-Gutiérrez, Myrna, et al.
Publicado: (2023)

Fluorescent, Plasmonic, and Radiotherapeutic Properties of the (177)Lu–Dendrimer-AuNP–Folate–Bombesin Nanoprobe Located Inside Cancer Cells
por: Mendoza-Nava, Héctor, et al.
Publicado: (2017)

(177)Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer
por: Santos-Cuevas, Clara, et al.
Publicado: (2018)

Chemo-radiotherapy with (177)Lu-PLGA(RGF)-CXCR4L for the targeted treatment of colorectal cancer
por: Cruz-Nova, Pedro, et al.
Publicado: (2023)

Improved quality control of [(177)Lu]Lu-PSMA I&T
por: Kraihammer, Martin, et al.
Publicado: (2023)

Theoretical and experimental characterization of emission and transmission spectra of Cerenkov radiation generated by (177)Lu in tissue
por: Jiménez-Mancilla, Nallely P., et al.
Publicado: (2019)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer
por: Weineisen, Martina, et al.
Publicado: (2014)

Biodistribution and dosimetry for combined [(177)Lu]Lu-PSMA-I&T/[(225)Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
por: Delker, Astrid, et al.
Publicado: (2023)

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

(177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T
por: Bundschuh, Ralph A., et al.
Publicado: (2023)

Automated radiosynthesis of [(68)Ga]Ga‐PSMA‐11 and [(177)Lu]Lu‐PSMA‐617 on the iPHASE MultiSyn module for clinical applications
por: Wichmann, Christian W., et al.
Publicado: (2020)

Synthesis and Evaluation of (177)Lu-DOTA-DN(PTX)-BN for Selective and Concomitant Radio and Drug—Therapeutic Effect on Breast Cancer Cells
por: Gibbens-Bandala, Brenda, et al.
Publicado: (2019)

Production and Quality Control of [(177)Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials
por: Di Iorio, Valentina, et al.
Publicado: (2022)

Ichthyosis follicularis, alopecia, and photophobia (IFAP) syndrome
por: Mégarbané, Hala, et al.
Publicado: (2011)

Response to (225)Ac-PSMA-I&T after failure of long-term (177)Lu-PSMA RLT in mCRPC
por: Ilhan, Harun, et al.
Publicado: (2020)

SUV(mean) on baseline [(18)F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2023)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617
por: de Bakker, Maarten, et al.
Publicado: (2023)

IFAP Syndrome with Rickets and Normal Vitamin D Status
por: Laway, Bashir Ahmad, et al.
Publicado: (2012)

A Case of IFAP Syndrome with Severe Atopic Dermatitis
por: Araújo, Catarina, et al.
Publicado: (2015)

Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology †
por: Rangger, Christine, et al.
Publicado: (2020)

Optimization of (177)Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application
por: Cankaya, Aylin, et al.
Publicado: (2023)

Pharmaceuticals—Special Issue on Radiopharmaceutical Chemistry between Imaging and Endoradiotherapy
por: Kopka, Klaus
Publicado: (2014)

Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases
por: Pfannkuchen, Nina, et al.
Publicado: (2017)

(131)I-C19 Iodide Radioisotope and Synthetic I-C19 Compounds as K-Ras4B–PDE6δ Inhibitors: A Novel Approach against Colorectal Cancer—Biological Characterization, Biokinetics and Dosimetry
por: Cruz-Nova, Pedro, et al.
Publicado: (2022)

Radiosynthesis and Preclinical Evaluation of Bispecific PSMA/FAP Heterodimers for Tumor Imaging
por: Hu, Kongzhen, et al.
Publicado: (2022)

Tolerability of concurrent external beam radiotherapy and [(177)Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial)
por: van der Sar, Esmée C. A., et al.
Publicado: (2023)

[(68)Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [(177)Lu]Lu-PSMA therapy in relapsing high-grade glioma
por: Truckenmueller, Peter, et al.
Publicado: (2022)

Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T
por: Brosch-Lenz, Julia, et al.
Publicado: (2021)

Combined external beam radiotherapy with carbon ions and tumor targeting endoradiotherapy
por: Melzig, Claudius, et al.
Publicado: (2018)

Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [(177)Lu]Lu-PSMA I&T during long-term follow-up
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

AlphaBet: Combination of Radium-223 and [(17)(7)Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)
por: Kostos, Louise, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8ll2s17ir4afpm67l43eicvdcu